Sam Brusco, Associate Editor07.25.23
Baxter rolled out its PerClot passive, absorbable hemostatic powder in the U.S. PerClot was designed for patients with intact coagulation to address mild bleeding, according to the company.
"PERCLOT is a strong complement to Baxter’s leading hemostat portfolio," Steve Wallace, Baxter’s president of Advanced Surgery told the press. "The launch of PERCLOT in the U.S. allows us to provide surgeons with a full range of active and passive hemostatic products for bleeding control, helping to optimize care for their patients."
PerClot polysaccharide granules feature a molecular structure that rapidly absorbs water to create a gelled adhesive matrix, which forms a mechanical barrier to stop further bleeding. The barrier also causes accumulation of platelets, red blood cells, and coagulation proteins (thrombin, fibrinogen, etc.).
Clinicians can use PerClot to address a wider variety of intraoperative bleeding, Baxter said, which can help to reduce blood transfusions and major complications, as well as lower the total cost of care. The adjunctive hemostatic device can be used to control bleeding during open and laparoscopic gynecologic, general, cardiovascular, and urology procedures.
To date, PerClot is sold in over 35 countries globally after acquiring the product in July 2021.
"PERCLOT is a strong complement to Baxter’s leading hemostat portfolio," Steve Wallace, Baxter’s president of Advanced Surgery told the press. "The launch of PERCLOT in the U.S. allows us to provide surgeons with a full range of active and passive hemostatic products for bleeding control, helping to optimize care for their patients."
PerClot polysaccharide granules feature a molecular structure that rapidly absorbs water to create a gelled adhesive matrix, which forms a mechanical barrier to stop further bleeding. The barrier also causes accumulation of platelets, red blood cells, and coagulation proteins (thrombin, fibrinogen, etc.).
Clinicians can use PerClot to address a wider variety of intraoperative bleeding, Baxter said, which can help to reduce blood transfusions and major complications, as well as lower the total cost of care. The adjunctive hemostatic device can be used to control bleeding during open and laparoscopic gynecologic, general, cardiovascular, and urology procedures.
To date, PerClot is sold in over 35 countries globally after acquiring the product in July 2021.